NRX Pharmaceuticals, Inc. (NRXP): Nasdaq/NYSE listing notice — NRX Pharma receives Nasdaq bid price deficiency notice; sues to unmask short attackers

NRX Pharmaceuticals, Inc.

Nasdaq notice on April 18, 2023: closing bid below $1.00 for 30 consecutive business days.
Company has 180 days (until Oct 16, 2023) to regain compliance; needs $1.00+ close for 10 days.
Filed NY State Supreme Court lawsuit to compel disclosure of identities posting false, derogatory info.
Commissioned expert counsel to assess impact of naked shorting and spoofing on stock.
Confirms strategic licensing discussions remain ongoing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 18, 2023, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Registrant was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the Registrant’s closing bid price for its common stock was below $1.00 per share for the last thirty (30) consecutive business days. Nasdaq’s notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market and, at this time, the common stock will continue to trade on The Nasdaq Global Market under the symbol “NRXP”. Pursuant to Nasdaq Listing Rule 5810(c)

View on SEC.gov

Browse all listing & compliance notices →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-048405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.